



## Osiris Therapeutics to Present at the 2008 UBS Global Life Sciences Conference

**Columbia, Maryland – September 18, 2008** – Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas, announced today that C. Randal Mills, Ph.D., President and CEO, is scheduled to present at the 2008 UBS Global Life Sciences Conference in New York on Tuesday, September 23, 2008, at 3:00 p.m. EDT.

A live audio webcast of the presentation may be accessed through the Investors page of the Company's website at [www.Osiris.com](http://www.Osiris.com). An audio replay of the webcast will be available for 30 days following the conference.

### About Osiris Therapeutics

Osiris Therapeutics, Inc. is a leading stem cell therapeutic company focused on developing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas. Prochymal is being evaluated in Phase III clinical trials for three indications, including acute and steroid refractory Graft versus Host Disease and also Crohn's disease, and is the only stem cell therapeutic currently designated by FDA as both an Orphan Drug and Fast Track product. Osiris also has partnered with Genzyme Corporation to develop Prochymal as a medical countermeasure to nuclear terrorism and other radiological emergencies. Furthermore, Prochymal is being developed for the repair of heart tissue following a heart attack, the protection of pancreatic islet cells in patients with type 1 diabetes, and the repair of lung tissue in patients with chronic obstructive pulmonary disease. The Company's pipeline of internally developed biologic drug candidates under evaluation also includes Chondrogen for arthritis in the knee. Osiris is a fully integrated company, having developed capabilities in research, development, manufacturing, and distribution of stem cell products. Osiris has developed an extensive intellectual property portfolio to protect the company's technology including 47 U.S. patents each having one or more foreign counterparts. Osiris, Prochymal and Chondrogen are registered trademarks of Osiris Therapeutics, Inc. More information can be found on the company's website, [www.Osiris.com](http://www.Osiris.com). (OSIR-G)

### Forward-Looking Statements

This press release may contain forward-looking statements. These forward-looking statements may generally be identified by the use of the words "may," "will," "expects," "anticipates," "believes," "estimates," and similar expressions, and involve a number of risks and uncertainties. For a variety of reasons, actual results may differ materially from those described in or contemplated by any such forward-looking statement. Consequently, the reader is cautioned to consider all forward-looking statements in light of the risks to which they are subject.

**For additional information, please contact:  
Erica Elchin, Osiris Therapeutics, Inc. at (443) 545-1834  
[OsirisPR@osiris.com](mailto:OsirisPR@osiris.com)**

**Media Contacts:  
Stacey Holifield/Andrew Law  
Schwartz Communications  
(781) 684-0770  
[Osiris@schwartz-pr.com](mailto:Osiris@schwartz-pr.com)**